RESUMEN
INTRODUCTION: The chronicity of advanced glycation end-products (AGEs) imparts various damages resulting in metabolic dysfunction and diseases involving inflammation and oxidative stress. The use of plant extracts is of high interest in complementary medicine. Yet, extracts are multicomponent mixtures, and difficult to pinpoint their exact mechanism. OBJECTIVES: We hypothesise that network pharmacology and bioinformatics can help experimental findings depict the exact active components and mechanism of action by which they induce their effects. Additionally, the toxicity and variability can be lowered and standardised with proper encapsulation methods. METHODOLOGY: Here, we propose the formulation of phytoniosomes encapsulating two Artemisia species (Artemisia dracunculus and Artemisia absinthium) to mitigate AGEs and their induced cell redox dysregulation in the liver. Extracts from different solvents were identified via liquid chromatography quadrupole time-of-flight mass spectrometry (LC-Q-TOF-MS/MS). Phytoniosomes were explored for their anti-glycating effect and modulation of AGE-induced damages in THLE-2 liver cells. Network pharmacology tools were used to identify possible targets and signalling pathways implicated. RESULTS: Data demonstrated that A. absinthium phytoniosomes had a significant anti-AGE effect comparable to reference molecules and higher than A. dracunculus. They were able to restore cell dysfunction through the restoration of tumour necrosis alpha (TNF-α), interleukin 6 (IL-6), nitric oxide, and total antioxidant capacity. Phytoniosomes were able to protect cells from apoptosis by decreasing caspase 3 activity. Network pharmacology and bioinformatic analysis confirmed the induction of the effect via Akt-PI3K-MAPK and AGE-RAGE signalling pathways through quercetin and luteolin actions. CONCLUSION: The current report highlights the potential of Artemisia phytoniosomes as strong contenders in AGE-related disease therapy.
Asunto(s)
Artemisia , Diabetes Mellitus , Medicamentos Herbarios Chinos , Antioxidantes/farmacología , Artemisia/química , Caspasa 3 , Cromatografía Liquida , Interleucina-6 , Hígado/metabolismo , Luteolina , Farmacología en Red , Óxido Nítrico , Fosfatidilinositol 3-Quinasas , Extractos Vegetales/química , Extractos Vegetales/farmacología , Proteínas Proto-Oncogénicas c-akt/metabolismo , Quercetina , Solventes , Espectrometría de Masas en Tándem/métodos , Factor de Necrosis Tumoral alfaRESUMEN
Artemisia herba-alba (AHA) is a traditionally used plant to treat various diseases, including diabetes and metabolic dysfunctions. Plant extracts are generally explored empirically without a deeper assessment of their mechanism of action. Here, we describe a combinatorial study of biochemical, molecular, and bioinformatic (metabolite-protein pharmacology network) analyses to elucidate the mechanism of action of AHA and shed light on its multilevel effects in the treatment of diabetes-related advanced glycation end-products (AGE)-induced liver damages. The extract's polyphenols and flavonoids content were measured and then identified via LC-Q-TOF-MS/MS. Active compounds were used to generate a metabolite-target interaction network via Swiss Target Prediction and other databases. The extract was tested for its antiglycation and aggregation properties. Next, THLE-2 liver cells were challenged with AGEs, and the mechanistic markers were measured [TNF-α, IL-6, nitric oxide, total antioxidant capacity, lipid peroxidation (LPO), and caspase 3]. Metabolite and network screening showed the involvement of AHA in diabetes, glycation, liver diseases, aging, and apoptosis. Experimental confirmation showed that AHA inhibited protein modification and AGE formation. Additionally, AHA reduced inflammatory mediators (IL-6, TNFα), oxidative stress markers (NO, LPO), and apoptosis (Caspase 3). On the other hand, cellular total antioxidant capacity was restored to normal levels. The combinatorial study showed that AHA regulates AGE-induced liver damages through MAPK-AKT and AGE-RAGE signaling pathways. This report highlights the combination of experimental and network pharmacology for the exact elucidation of AHA mechanism of action as a multitarget option in the therapy of diabetes and AGEs-related diseases.
Asunto(s)
Artemisia , Diabetes Mellitus , Antioxidantes/farmacología , Artemisia/metabolismo , Caspasa 3/metabolismo , Diabetes Mellitus/tratamiento farmacológico , Flavonoides/farmacología , Productos Finales de Glicación Avanzada/metabolismo , Mediadores de Inflamación/metabolismo , Interleucina-6/metabolismo , Hígado/metabolismo , Óxido Nítrico/metabolismo , Extractos Vegetales/farmacología , Polifenoles/farmacología , Proteínas Proto-Oncogénicas c-akt/metabolismo , Receptor para Productos Finales de Glicación Avanzada/metabolismo , Transducción de Señal , Espectrometría de Masas en Tándem , Factor de Necrosis Tumoral alfa/metabolismoRESUMEN
The planting of several species adapted to forests areas in the Saharan Atlas would allow one to better fight against the desertification of the vegetation cover of these fragile areas. Thanks to its rapid growth on degraded soils, Robinia pseudoacacia L. has an advantage in the repopulation of these areas undergoing desertification. Operation of this large-scale tree requires good control of germination conditions and growth of plants. The scarification of the seeds of Robinia pseudoacacia L. is necessary to allow the absorption of water by the seeds. Our results show that mechanical scarification with sulphuric acid (75minutes), boiling water (90minutes) and scarification by microwaves (700W) (105seconds) give the best germination rates. The presence of PEG6000 in the imbibition's solutions reduces considerably the germination rate of the seeds of R. pseudoacacia L. A 70 % decrease in the optimal rate of germination is observed when the osmotic pressure of the imbibition solution is at -4.65 bar.